---
schema_version: "secwatch.filing_event.v1"
accession: "0001127537-22-000009"
form_type: "8-K/A"
ticker: "LUNG"
cik: "0001127537"
company_name: "Pulmonx Corp"
filed_at: "2022-02-25T23:59:59+00:00"
generated_at: "2026-06-27T04:02:23.436600+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pulmonx Q4 revenue $13.7M (+39% YoY); FY2022 guidance $55M-$60M

## Summary
- Q4 2021 revenue $13.7M, up 39% YoY; FY2021 revenue $48.4M, up 48% YoY.
- Gross margin improved to 74.8% in Q4 and 73.6% for FY2021, vs 72.0% and 64.8% a year ago.
- Net loss Q4 $13.0M ($0.35/sh); FY net loss $48.7M ($1.35/sh).
- FY2022 revenue guidance $55M-$60M; Q1 2022 guidance $9M-$10M, reflecting COVID impact.
- U.S. treatment centers for Zephyr Valves expanded to 214, up 45% from start of 2021.

## SEC filing metadata
- accession: 0001127537-22-000009
- form_type: 8-K/A
- ticker: LUNG
- cik: 0001127537
- company_name: Pulmonx Corp
- filed_at: 2022-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1127537/000112753722000009/0001127537-22-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1127537/000112753722000009/lung-20220223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001127537-22-000009
- JSON: https://secwatch.observer/filing/0001127537-22-000009.json
- Plain text: https://secwatch.observer/filing/0001127537-22-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.